<DOC>
	<DOCNO>NCT02465567</DOCNO>
	<brief_summary>This randomize , double-blind , multi-center , parallel-group study ass efficacy safety PT010 relative PT003 PT009 COPD exacerbation subject moderate severe COPD .</brief_summary>
	<brief_title>Study Assess Efficacy Safety PT010 Relative PT003 PT009 Subjects With Moderate Very Severe COPD ( Ethos )</brief_title>
	<detailed_description>A randomized , double-blind , multi-center , parallel-group study ass efficacy safety PT010 relative PT003 PT009 COPD exacerbations 52-week treatment period subject moderate severe COPD .</detailed_description>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<criteria>Inclusion Criteria Nonchild bear potential ( ie , physiologically incapable become pregnant , include female 2 year postmenopausal ) ; Child bear potential , negative serum pregnancy test Visit 1 , agree acceptable contraceptive method use consistently correctly duration study . Subjects establish clinical history COPD define American Thoracic Society ( ATS ) /European Respiratory Society ( ERS ) , Current former smoker history least 10 packyears cigarette smoking . Forced expiratory volume 1 second ( FEV1 ) /Forced vital capacity ( FVC ) ratio must &lt; 0.70 FEV1 must &lt; 65 % predict normal value calculate use NHANES III reference equation ( reference norm applicable region ) . Subjects history exacerbation . Please refer study protocol complete inclusion criterion list . Exclusion Criteria Significant diseases condition COPD , , opinion Investigator , may put subject risk participation study may influence either result study subject 's ability participate study . Women pregnant lactating , plan become pregnant course study , woman childbearing potential use acceptable method contraception . Subjects , opinion Investigator , current diagnosis asthma . Subjects hospitalize due poorly control COPD within 3 month prior Visit 1 ( Screening ) Subjects poorly control COPD , define acute worsen COPD require treatment oral corticosteroid antibiotic within 6 week prior Visit 1 ( Screening ) Immune suppression severe neurological disorder affect control upper airway risk factor opinion Investigator would put subject substantial risk pneumonia . Subjects diagnosis narrow angle glaucoma , , opinion Investigator , adequately treat . Subjects history hypersensitivity Î²2agonists , budesonide corticosteroid component , glycopyrronium muscarinic anticholinergic , component IMPs . Please refer study protocol complete inclusion criterion list .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>